Exact Sciences to participate in J.P. Morgan Healthcare Conference
MADISON, Wis., Jan. 2, 2024 /PRNewswire/ — Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
Related news for (EXAS)
- Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap
- Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
- Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium
- Exact Sciences Announces Preliminary Fourth Quarter 2024 Results
- Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy